Johnson & Johnson (JNJ)vsWaystar Holding Corp. Common Stock (WAY)
JNJ
Johnson & Johnson
$227.35
-0.19%
HEALTHCARE · Cap: $547.64B
WAY
Waystar Holding Corp. Common Stock
$25.27
+0.16%
HEALTHCARE · Cap: $4.88B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 8666% more annual revenue ($96.36B vs $1.10B). JNJ leads profitability with a 21.8% profit margin vs 10.2%. JNJ trades at a lower P/E of 26.4x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
WAY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-42.0%
Fair Value
$160.13
Current Price
$227.35
$67.22 premium
Margin of Safety
+3.5%
Fair Value
$24.59
Current Price
$25.27
$0.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 23.6%
Revenue surging 24.3% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Distress zone — elevated risk
ROE of 3.2% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : WAY
The strongest argument for WAY centers on Price/Book, Debt/Equity, Operating Margin. Revenue growth of 24.3% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : WAY
The primary concerns for WAY are Altman Z-Score, Return on Equity, Piotroski F-Score. A P/E of 41.7x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while WAY is a growth play — different risk/reward profiles.
WAY is growing revenue faster at 24.3% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 51/100), backed by strong 21.8% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Waystar Holding Corp. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Waystar Holding Corp. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?